Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Elevated circulating lactate in late-stage melanoma patients.
Journal: QJM : monthly journal of the Association of Physicians
Published: February 25, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer.
Journal: Research square
Published: February 23, 2026
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer.
Journal: Breast cancer research : BCR
Published: December 20, 2025
Survival Outcomes in Stage III to IV Melanoma Before and After the Immunotherapy Era: Persistent Racial and Socioeconomic Disparities.
Journal: JCO oncology practice
Published: October 13, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2025
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2025
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors.
Journal: Cancer communications (London, England)
Published: January 24, 2025
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 19, 2024
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.
Journal: The oncologist
Published: June 03, 2024
Last Updated: 09/26/2026